FBXO17 could promote liver cancer progression via the Wnt/β-catenin pathway and accelerate lung adenocarcinoma cell proliferation by activating the Akt pathway (Suber et al., 2018; Liu et al., 2019). Here, AKT1 is linked to liver cancer.